Agendia Receives €1.27 Million in Funding from the EU’s Seventh Framework Programme

IRVINE, California and AMSTERDAM, July 21, 2011 -

- Company Will Develop Companion
Diagnostics With Consortiums of Leading European Cancer Centers and
Translational Research Groups

Agendia, a global innovator in molecular cancer diagnostics,
announced today that, together with thought-leading collaborators
in clinical centers and translational research groups, it has
launched the RATHER (Rational Therapy for Breast Cancer) and
COLTHERES (Colon Cancer and Therapeutics) consortiums. The
partnerships will collectively receive nearly €12 million in
funding from the European Union’s 7^th Framework
Programme over a five-year term. Agendia, in particular, will
receive €1.27 million for the development of new molecular
diagnostics to help guide individualized treatment of cancer
patients.

Both consortiums will be focused on gaining deeper insight into
molecular subtypes of breast and colon cancer, and the development
of biomarkers for use in predicting patients’ individual responses
to new targeted drugs. While RATHER seeks to improve treatment for
triple negative and lobular breast cancer patients, COLTHERES is
focused on response or resistance to targeted therapeutics in colon
cancer. Both consortiums consist of clinical partners as well as
leading translational research groups with a proven track record in
developing companion diagnostics for cancer therapies. The
objective of these partnerships is to define and perform
biomarker-driven clinical trials to improve cancer therapy
outcomes, with Agendia developing reliable and standardized
biomarker tests.

Other members of the consortiums include the University College
Dublin, the Netherlands Cancer Institute (NKI) Amsterdam, Institute
Curie Paris, Malmö University Hospital Lund, Vall d’Hebron
Barcelona, University of Cambridge, OncoMark Ltd Dublin, University
of Leuven, Niguarda Ca’ Granda Hospital Milano, IDIBELL Barcelona,
Horizon Discovery UK, University of Liverpool, Swiss Institute of
Bioinformatics and the University of Torino School of Medicine.

“We are pleased to participate in these EU funded projects and
to work with these outstanding international experts in the fields
of functional genomics, pharmacogenetics, bio-informatics and
clinical oncology,” said Prof. Dr. Rene Bernards, CSO of Agendia.
“For Agendia, this is a great opportunity to develop new companion
diagnostics together with a large group of scientists and
physicians to address urgent clinical needs. The unique consortium
structures will allow a rapid translation of results from research
and discovery into a clinical setting that benefits patients.”

About Agendia:

Agendia is a leading global
commercial molecular diagnostic company that develops and markets
genomic-based diagnostic products that improve the quality of life
for cancer patients and simplifies complex treatment decisions for
their physicians. Agendia’s Symphony™ suite of breast cancer
products is based on the analysis of hundreds of genes in a
patient’s breast and provides unprecedented biological insight to
address complex treatment decisions. Symphony™ includes
MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer
recurrence assay, as well as BluePrint®, a molecular subtyping
assay, TargetPrint®, an ER/PR/HER2 expression assay, and
TheraPrint®, a therapy selection assay. Together, these tests help
physicians determine a patient’s individual risk for metastasis,
which patients will benefit from chemo or hormonal therapy, and who
can instead be treated with other less arduous and costly
methods.

In addition to the Symphony™ suite of tests, Agendia has a rich
pipeline of genomic products in development based on its
world-class genomic platform. The company also collaborates with
pharmaceutical companies to develop companion diagnostic tests in
the area of oncology and is a critical partner in the ISPY-2 and
MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Amsterdam, the Netherlands, and
Irvine, California, United States. For more information, please
visit href="www.agendia.com">www.agendia.com.

For more information on COLTHERES consortium go to href="www.coltheres.eu/">www.coltheres.eu/. For
more information on the RATHER Project go to href="www.ratherproject.com/">www.ratherproject.com/.

For further information, please contact: International media and investor inquiries, M:Communications, Peter Laing / Amber Bielecka, Tel: +44(0)20-7920-2352, E-mail: Agendia at mcomgroup.com; US media inquiries, Ricochet Public Relations, Valerie Carter, Tel: +1-202-316-0143, E-mail: vcarter at ricochetpr.com